There has been a rapid increase in adjuvant therapies approved for treatment following surgical resection of stages III/IV melanoma. We review current indications for adjuvant therapy, which currently includes a heterogenous group of stages III and IV patients with melanoma. We describe several pivotal clinical trials of systemic immune therapies, targeted immune therapies, and adjuvant vaccine strategies. Finally, we discuss the evidence for selecting the most appropriate treatment regimen(s) for the individual patient.
There has been a rapid increase in adjuvant therapies approved for treatment following surgical resection of stages III/IV melanoma. We review current indications for adjuvant therapy, which currently includes a heterogenous group of stages III and IV patients with melanoma. We describe several pivotal clinical trials of systemic immune therapies, targeted immune therapies, and adjuvant vaccine strategies. Finally, we discuss the evidence for selecting the most appropriate treatment regimen(s) for the individual patient. 1,2 Subsequently, these same treatments have been shown to improve recurrence-free survival (RFS) in the adjuvant treatment of high-risk, resected patients with melanoma. 1, [3] [4] [5] [6] [7] [8] The decision to recommend adjuvant therapy after surgery for melanoma is based on the relative risk of recurrence, specific tumor characteristics that impact drug selection (eg, BRAF V600E or V600K mutation), risks associated with treatment, and patientrelated factors that affect the ability to tolerate therapy. In this review, we will discuss indications for adjuvant therapy, key findings from landmark adjuvant therapy trials, preferred choices of adjuvant therapy, and future directions. 9 
| DEFINING HIGH-RISK POPULATIONS FOR WHOM ADJUVANT THERAPY IS APPROPRIATE
The decision to recommend adjuvant therapy after surgery for melanoma is based on the risk of recurrence. Before surgery, some patients will have known American Joint Committee on Cancer (AJCC) version 8 stage IIIB or higher disease including patients with clinically detected lymph nodes, or clinically detected stage IV disease. In a large cohort study in an era preceding the liberal use of effective adjuvant therapy, only 32% with stage IIIB and 11% of patients with stage IIIC (AJCC v7) were alive without recurrence at 5 years after surgical resection. 10 Given the high rate of recurrence in these patients, all of the recent adjuvant trials included these types of stage III patients. [3] [4] [5] The inclusion of stage IV patients was limited to Checkmate-238. Before approval of multiple new effective therapies for unresectable stages III and IV melanoma, surgical resection remained a therapeutic option for many patients with stage IV melanoma. 11 However, in the current era, surgery should be considered only in selected cases of stage IV disease given the improvements in systemic therapy.
Many patients are diagnosed with stage III melanoma after wide local excision and a positive sentinel lymph node biopsy (SLNB). In the final analysis of the multicenter selective lymphadenectomy trial I (MSLT-1), SLNB positivity was associated with an increased risk of disease recurrence compared with SLNB-negative patients with the hazard ratio (HR) of 2.64 (95% confidence interval [CI], 1.92-3.64;
will less frequently be used to further stratify patients at high-risk of recurrence and death from melanoma. 12, 15 Beyond NSLN involvement, the maximum tumor diameter in the SLN has been found to predict disease-free survival and overall survival (OS) in patients with melanoma. 16 Patients with 1 mm or less tumor in the SLN have a 10-year melanoma-specific mortality of less than 10%. 15 In other studies, a cutoff of 1 mm of tumor in the SLN was shown to select patients with excellent survival. 17, 18 Thus, eligibility for many adjuvant trials included patients with 1 mm of tumor in the SLN including EORTC 1325, EORTC 18071, SWOG 1404, COMBI-AD, and BRIM8. 5, 6, 8, 19 Even among patients with SLNB-positive disease with greater than 1 mm of tumor, there remains heterogeneity in the risk of recurrence. Both the tumor burden in the SLN and ulceration of the primary tumor have been explored by the Netherlands Cancer
Institute Group as another method to predict which patients will benefit from adjuvant therapy and which patients need no additional therapy after a positive SLNB. 20 In their analyses, AJCC v8 staging plus sentinel node (SN) tumor burden allowed more distinct risk stratification and was the best performing model at predicting recurrence. expression. 5 Similar to Checkmate-238, this trial's secondary endpoint of OS is pending. Importantly, however, this trial allows crossover to pembrolizumab at progression, and it may help answer questions around the optimal timing of systemic therapy in this patient population.
Pembrolizumab as adjuvant therapy is also being studied in SWOG 1404, a randomized trial comparing IFN-α (amended to also of nivolumab plus 1 mg/kg of ipilimumab every 3 weeks for four doses (n = 2) followed by the same maintenance regimen for both groups, nivolumab at 3 mg/kg every 2 weeks for 2 years. 36 Among all 40 patients, the median RFS has not been reached yet at a median follow-up of 2.9 years. 36 However, the toxicity of the combination appeared higher than in the metastatic setting. 
| ADJUVANT TARGETED THERAPY
In addition to immune therapy, adjuvant targeted therapy for the approximately 50% of patients with melanoma whose melanomas harbor a BRAF V600E or V600K mutation has also been studied. 4, 8 In patients with unresectable stages III and IV melanoma, the combination of BRAF and MEK inhibition (BRAFi/MEKi) is associated with high Other potential neoantigen strategies include phosphopeptides that reflect cancer-associated phosphoprotein targets. 44 These antigen strategies alone are generally not enough to elicit a strong, prolonged immune response and so are combined with "vaccine adjuvants."
Vaccine adjuvants are aimed at producing a more robust immune response by increasing antigen uptake and presentation, recruiting other immune cells, promoting antigen transport to lymph nodes, and forming a depot effect for sustained release of antigen at the site of injection. [45] [46] [47] One example of a melanoma vaccine that has shown promise in clinical trials of patients with melanoma is the 6-melanoma helper peptide (6-MHP) vaccine. [48] [49] [50] [51] . 48 Vaccines to induce helper T-cells offer promise in part to create a memory response through Th1, but to also elicit effector T-cell and dendritic cell responses, laying the groundwork for the secretion of cytokines to promote a stronger immune response. [54] [55] [56] [57] An important breakthrough in vaccine development for stages III and IV patients with melanoma is described in two recent papers published in the same issue of Nature in 2017. 42, 43 Both studies used neoantigen vaccines as a means of personalized vaccine development based on predicted immunopeptides from melanoma genome mutations. These predicted neoantigens were synthesized through complex algorithms to predict immunologic responses, comparing the exome sequencing of matched tumor cells to normal cells. Both studies showed their predicted neoantigens allowed for an effective means of immunologic and therapeutic effectiveness against stage III melanoma after surgical resection during the short follow-up period of 12 to 25 months. 42, 43 However, results were more mixed for patients with stage IV disease and for patients that had signs of recurrence shortly after study inclusion.
This method of personalized neoantigen vaccines still needs further investigation to ensure its safety and effectiveness as it requires a significant amount of time and resources. There are other challenges to this approach, as well, since a wide array of neoantigen heterogeneity may be present in different sites of metastasis in the same patients. 58 As we gain more knowledge into these different vaccine strategies and how to best combine them with other immunotherapies, we advance our understanding of the interplay between the immune system and tumor biology to not only develop a therapeutic agent but to also develop long-term efficacy against the progression of future disease.
| COST OF ADJUVANT THERAPY IN MELANOMA
There are significant costs associated with systemic therapy for melanoma that should be considered when determining how these recommendations will be applied in the adjuvant setting. found nivolumab monotherapy to be more cost-effective than nivolumab-ipilimumab combination therapy, which was, in turn, more cost-effective than ipilimumab monotherapy in patients with metastatic melanoma. 61 Importantly, these analyses took into account the costs of AEs in addition to direct medical costs of the drugs.
Targeted therapies for melanoma are also associated with significant costs. In 2014, vemurafenib cost $13 000 per month for a total of $207 000 for a patient with median survival, while dabrafenib cost $9 100 per month. 62 
| Changes to surgical practice
Given the data, our current surgical practice has evolved. A surgeon operating on a patient with known stage III (in-transit, palpable An additional consideration for the surgeon is to perform SLNB for an in-transit or satellite lesion given our group has reported a 40% rate of SLNB positivity in those patients. 66 At the time of that publication, the only adjuvant therapy approval was for ipilimumab which required 1 mm of SLNB involvement. Given that both PD-1 antibody and targeted therapy BRAFi/MEKi are available after resection of IT disease only (no nodal disease required), SLNB of IT or recurrent subcutaneous disease should be considered only in selected circumstances where SLNB positivity may clarify the riskbenefit ratio for adjuvant therapy. 
| Choice of therapy based on efficacy

| FUTURE DIRECTIONS AND CONCLUSION
As data from Checkmate-915, an RCT of adjuvant nivolumab and ipilimumab, ECOG1609 (NCT01274338), an RCT of low vs high-dose ipilimumab vs IFN-α, and adjuvant vaccine trials becomes available, it is likely the choices for adjuvant therapy will continue to expand.
Given experience in the metastatic setting, adjuvant nivolumab and ipilimumab may result in the most efficacious risk reduction strategy but will likely come at the cost of toxicity. In future adjuvant therapy trials, it will be difficult to justify comparison to a placebo arm because of the approved adjuvant therapies now available. New therapies will have a higher standard to meet. Going forward, patients should also be encouraged to participate in clinical trials after resection of high-risk melanoma especially when novel therapies might have a more acceptable safety profile.
There are several studies examining the role of neoadjuvant therapy in the setting of technically resectable disease that has shown some promising results that may change the paradigm for some patients. [67] [68] [69] 
